)
Edge6 Mar 2026
Upvoted: The Story of Reddit
How Reddit built a unique platform around communities and conversation, turning human insight and intent into a distinctive business model.
Tenaya Therapeutics
Tenaya Therapeutics (TNYA) investor relations material
Tenaya Therapeutics Q4 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q4 2025 earnings summary11 Mar, 2026
Executive summary
Reported promising clinical data for TN-201 and TN-401 gene therapies in Q4 2025, with additional data readouts and regulatory alignment planned for 2026.
Entered a multi-target research collaboration with Alnylam Pharmaceuticals, including an upfront payment and potential milestones.
December 2025 financing raised $55.8M, extending cash runway into the second half of 2027.
Financial highlights
Cash, cash equivalents, and marketable securities totaled $100.5M as of December 31, 2025, up from $61.4M at year-end 2024.
R&D expenses were $14.8M for Q4 and $68.6M for FY 2025, down from $18.7M and $86.7M in 2024.
G&A expenses were $6.0M for Q4 and $24.7M for FY 2025, compared to $6.0M and $29.2M in 2024.
Net loss for Q4 2025 was $20.2M ($0.12/share), and $90.6M ($0.59/share) for FY 2025, both improved from prior year.
Outlook and guidance
Cash resources, including proceeds from the public offering and Alnylam collaboration, expected to fund operations into the second half of 2027.
Plans to share additional clinical data and pursue regulatory alignment for TN-201 and TN-401 pivotal trials in 2026.
Advancement of TN-301 toward clinical trials in HFPEF and DMD indications planned for 2026.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Tenaya Therapeutics
- Advancing gene therapies and small molecules, with new partnerships and pivotal data expected this year.TNYA
Leerink Global Healthcare Conference 20269 Mar 2026 - TN-201 phase 1b data expected H2; gene therapy targets large unmet needs in HCM and ARVC.TNYATD Cowen Genetic Medicines & RNA Summit3 Feb 2026
- Initial TN-201 gene therapy data for HCM expected this year, with broader updates in 2025.TNYAMorgan Stanley 22nd Annual Global Healthcare Conference22 Jan 2026
- TN-201 gene therapy shows early safety, robust cardiac delivery, and promising clinical signals.TNYAStudy Update11 Jan 2026
- Gene therapies for HCM and ARVC show strong early results, advancing toward pivotal trials.TNYACorporate Presentation9 Jan 2026
- Gene therapy programs for heart disease show early promise, with pivotal data expected in 2025-2026.TNYATD Cowen 45th Annual Healthcare Conference26 Dec 2025
- Gene therapy and small molecule programs advance toward key data and partnership milestones.TNYALeerink’s Global Healthcare Conference 202526 Dec 2025
- Biotech seeks up to $300M to fund gene therapy pipeline, with $69.8M at-the-market offering.TNYARegistration Filing16 Dec 2025
- TN-401 gene therapy is safe and reduces arrhythmias in PKP2-associated ARVC.TNYAStudy Result13 Dec 2025
Next Tenaya Therapeutics earnings date
Q1 20267 May, 2026
Tenaya Therapeutics
Next Tenaya Therapeutics earnings date
Q1 20267 May, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Tenaya Therapeutics Inc. is a biotechnology company focused on discovering, developing, and delivering therapies for heart disease. The company's approach involves multiple therapeutic modalities, including gene therapy, cellular regeneration, and precision medicine, to address both rare genetic and prevalent forms of cardiovascular disease. Tenaya's research aims to target the underlying causes of heart disease, offering potential treatments for conditions that currently have limited therapeutic options. The company is headquartered in South San Francisco, California, and its shares are listed on the Nasdaq.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage